C3J Therapeutics

Los Angeles, United States Founded: 2006 • Age: 20 yrs
Pathogen-specific antimicrobials are developed for microbial dysbiosis diseases.
Request Access

About C3J Therapeutics

C3J Therapeutics is a company based in Los Angeles (United States) founded in 2006.. C3J Therapeutics has raised $214.5 million across 9 funding rounds from investors including HHS, Renaissance Acquisition Holdings and Delta Dental. The company has 60 employees as of December 31, 2021. C3J Therapeutics offers products and services including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03. C3J Therapeutics operates in a competitive market with competitors including Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.

  • Headquarter Los Angeles, United States
  • Employees 60 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name C3j Therapeutics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $214.5 M (USD)

    in 9 rounds

  • Latest Funding Round
    $19 M (USD), Series D

    Dec 14, 2016

  • Investors
    HHS

    & 2 more

  • Employee Count
    60

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of C3J Therapeutics

C3J Therapeutics offers a comprehensive portfolio of products and services, including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Technology for targeting and destroying bacterial pathogens.

System for developing engineered phages against infections.

Therapeutic for specific bacterial infections and resistance.

Advanced phage therapy for combating resistant bacteria.

Funding Insights of C3J Therapeutics

C3J Therapeutics has successfully raised a total of $214.5M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $19 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series D — $19.0M
  • First Round

    (17 Aug 2009)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2016 Amount Series D - C3J Therapeutics Valuation

investors

Dec, 2015 Amount Grant - C3J Therapeutics Valuation

investors

HHS
Mar, 2014 Amount Series D - C3J Therapeutics Valuation Renaissance Acquisition Holdings
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in C3J Therapeutics

C3J Therapeutics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Renaissance Acquisition Holdings and Delta Dental. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Online gaming and gambling platform
Founded Year Domain Location
Dental insurance plans are offered by Delta Dental nationwide.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by C3J Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - C3J Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

C3j Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of C3J Therapeutics

C3J Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of diagnostic solutions for systemic infections
domain founded_year HQ Location
Provider of machine learning based diagnostic solutions for infectious diseases
domain founded_year HQ Location
Instruments and test panels for multiplexed molecular diagnostics are provided.
domain founded_year HQ Location
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
domain founded_year HQ Location
Miniaturized MRI platforms for clinical diagnostics are developed.
domain founded_year HQ Location
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about C3J Therapeutics

When was C3J Therapeutics founded?

C3J Therapeutics was founded in 2006 and raised its 1st funding round 3 years after it was founded.

Where is C3J Therapeutics located?

C3J Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.

Is C3J Therapeutics a funded company?

C3J Therapeutics is a funded company, having raised a total of $214.5M across 9 funding rounds to date. The company's 1st funding round was a Series D of $60.5M, raised on Aug 17, 2009.

How many employees does C3J Therapeutics have?

As of Dec 31, 2021, the latest employee count at C3J Therapeutics is 60.

What does C3J Therapeutics do?

C3J Therapeutics was established in 2006 in Los Angeles, United States, with operations centered on the biotechnology sector. Specifically targeted antimicrobial peptides (STAMPs) are advanced for treating and preventing conditions linked to microbial dysbiosis. Key pipeline elements include C16G2, advanced to Phase 2 for dental caries prevention, and CD17-DL, in Phase 1 for C. difficile infection management. A PCR-based diagnostic for S. mutans detection is also in development.

Who are the top competitors of C3J Therapeutics?

C3J Therapeutics's top competitors include Visby Medical, Inflammatix and MeMed.

What products or services does C3J Therapeutics offer?

C3J Therapeutics offers Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03.

Who are C3J Therapeutics's investors?

C3J Therapeutics has 3 investors. Key investors include HHS, Renaissance Acquisition Holdings, and Delta Dental.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available